Markets:

Overview

News

Currencies

International

Treasuries

MBX Biosciences, Inc. - Common Stock (NQ:MBX)

57.72 +1.39 (+2.47%)

Delayed Quote Updated: 4:00 PM EST, Nov 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MBX Biosciences, Inc. - Common Stock

< Previous 1 2 Next >

Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide Market

November 05, 2026

New HHS Direction Creates Potential Opportunities for Peptide Manufacturers, Biotech Companies, and Healthcare Innovators

From FN Media

Via GlobeNewswire

Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across The $164 Billion Peptide Market

November 05, 2026

EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NASDAQ:MBX),(NASDAQ:KLRA),(NASDAQ:ALT),(NYSE:HIMS) EQNX::TICKER_END

Via FinancialNewsMedia

These stocks that are showing activity before the opening bell on Friday. ↗

June 12, 2026

Via Chartmill

MBX Stock Soars Pre-Market After Investigational Hypoparathyroidism Drug Yields Positive Results In Study ↗

September 22, 2025

Via Stocktwits

Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run ↗

May 27, 2026

MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider sale after a year of rapid stock gains.

Via The Motley Fool

Topics Regulatory Compliance

MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push ↗

May 11, 2026

MBX Biosciences (NASDAQ:MBX) used its Obesity Day event to outline preliminary clinical data for its lead obesity candidate MBX 4291, introduce a new preclinical obesity program and reiterate key...

Via MarketBeat

3 Overlooked Stocks Set to Soar in 2026 ↗

May 05, 2026

These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.

Via The Motley Fool

Aaron Wealth Makes a Big Bet on MBX Biosciences With a 1.1 Million Share Purchase ↗

April 22, 2026

MBX Biosciences targets endocrine and metabolic disorders with novel peptide therapies, advancing candidates across several clinical phases.

Via The Motley Fool

MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know ↗

March 26, 2026

Focused on precision therapies for endocrine disorders, this biotech firm reported a notable insider buy amid a year of sharp stock gains.

Via The Motley Fool

Topics Regulatory Compliance

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

This Twist Bioscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

November 04, 2025

Via Benzinga

Which stocks have an unusual volume on Thursday? ↗

September 25, 2025

Let's have a look at the stocks with an unusual volume in today's session.

Via Chartmill

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 25, 2025

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Thursday. Shares of Stitch Fix, Inc. (NASDAQ: SFIX) dipped 7.6% to $5.21 in pre-market trading following the...

Via Benzinga

Topics Stocks

Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗

September 25, 2025

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.

Via Benzinga

Unusual volume stocks are being observed in Tuesday's session. ↗

September 23, 2025

On Tuesday, there are stocks with unusual volume. Let's take a look.

Via Chartmill

Stock Market Today: Nasdaq Futures Rise, S&P 500 Slips Amid Mixed Trade—Kenvue, Micron Tech, Nvidia In Focus ↗

September 23, 2025

U.S. stock futures were fluctuating on Tuesday following Monday's record advances. Futures of major benchmark indices were mixed.

Via Benzinga

Topics Stocks

AutoZone, Micron Technology And 3 Stocks To Watch Heading Into Tuesday ↗

September 23, 2025

U.S. stock futures down, focus on AutoZone, Firefly Aerospace earnings, AAR Corp. results, MBX Biosciences public offering.

Via Benzinga

Top stock movements in today's session. ↗

September 22, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 22, 2025

Via Benzinga

Top movers analysis in the middle of the day on 2025-09-22: top gainers and losers in today's session. ↗

September 22, 2025

Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Gold Gains Over 1%; Quantum Computing Shares Plunge ↗

September 22, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

September 22, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

PROS Holdings, MBX Biosciences, Metsera, Anywhere Real Estate And Other Big Stocks Moving Higher On Monday ↗

September 22, 2025

Via Benzinga

Dow Falls Over 100 Points; Chicago Fed National Activity Index Rises In August ↗

September 22, 2025

Via Benzinga

Topics Economy Stocks

MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise ↗

September 22, 2025

The company is working on an experimental treatment for a thyroid disease.

Via Investor's Business Daily

Monday's pre-market session: top gainers and losers ↗

September 22, 2025

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study ↗

September 22, 2025

MBX Biosciences reported Phase 2 trial success for once-weekly canvuparatide, with strong efficacy, safety profile, and plans for Phase 3 in 2026.

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

MBX Biosciences, Inc. - Common Stock (NQ:MBX)

All News about MBX Biosciences, Inc. - Common Stock

Starting at /week.